Chronic Obstructive Pulmonary Disease News and Research

Latest Chronic Obstructive Pulmonary Disease News and Research

UNC receives grants from FDA and NIH to establish Tobacco Centers of Regulatory Science

The University of North Carolina at Chapel Hill received two separate grants from the U.S. Food and Drug Administration and the National Institutes of Health today as part of an on-going interagency partnership. UNC will house two of 14 Tobacco Centers of Regulatory Science, which are receiving a total of up to $53 million for tobacco-related research in fiscal year 2013.

21 Sep 2013

Inhaled corticosteroid increases risk for pneumonia reoccurrence

A University of Alberta researcher says health professionals should be cautious about prescribing inhaled corticosteroids to high-risk patients such as pneumonia survivors, citing a twofold risk for repeat infection.

19 Sep 2013

GERD prevalence raised even in mild–moderate COPD, bronchiectasis

Researchers from Australia have found that the rate of gastroesophageal reflux disease is twice as high in patients with chronic obstructive pulmonary disease or bronchiectasis as in people without lung disease.

18 Sep 2013

Emotional stress, cognitive impairment linked to early hospital readmission of heart patients

Heart patients' mental state and thinking abilities may help predict whether costly and potentially dangerous early hospital readmission will follow their release after treatment, according to the results of a significant new study by Henry Ford Hospital researchers.

18 Sep 2013

Dual-pronged approach to diabetes and COPD needed

Researchers from the USA have found that patients with diabetes and a history of smoking have significantly impaired lung function, even in the absence of overt chronic obstructive pulmonary disease.

17 Sep 2013

Attention drawn to COPD in never smokers

Research from Denmark shows that, while never smokers with chronic obstructive pulmonary disease typically experience milder disease than their smoking counterparts, they still have substantial morbidity due to COPD- and pneumonia-related hospital admissions.

16 Sep 2013

Phone support boost to COPD patients

Researchers from Australia have found that even brief phone contact from medical professionals can provide benefits to patients with chronic obstructive pulmonary disease.

16 Sep 2013

Inhaled corticosteroids increase pneumonia risk in asthma

Research from the UK indicates that the use of inhaled corticosteroids is independently associated with an increased risk for pneumonia and lower respiratory tract infection in patients with asthma.

12 Sep 2013

Improved lung function in patients with moderate asthma severity observed with investigational Tiotropium

Boehringer Ingelheim will present a pooled analysis of new data from the Phase 3 UniTinA-asthma® program at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona. The data from the individual MezzoTinA-asthma® Phase 3 studies (NCT01340209 and NCT00565266), from which the pooled data are derived, show the addition of tiotropium delivered via the Respimat® inhaler to medium-dose maintenance inhaled corticosteroid (ICS) therapy (defined as 400-800 µg budesonide/day or equivalent) improved lung function and provided sustained bronchodilation over 24 hours in patients with moderate asthma and airflow limitation. Tiotropium is being investigated to determine the medicine’s efficacy in treating asthma patients and is not currently approved for this indication.

11 Sep 2013

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

10 Sep 2013

Patients with COPD show improvements in lung function with olodaterol

Data from the olodaterol Phase 3 clinical program, presented for the first time at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona, showed the addition of olodaterol 5 and 10 µg delivered once daily via the Respimat® inhaler provided improvements in lung function in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

10 Sep 2013

Drug can be delivered safely to people with COPD in both "mist" and "dry powder" inhalers, say experts

An international study led by a Johns Hopkins pulmonary expert finds that the drug tiotropium (marketed as the Spiriva brand), can be delivered safely and effectively to people with chronic obstructive pulmonary disease (COPD) in both "mist" and traditional "dry powder" inhalers.

10 Sep 2013

Once-daily COPD portfolio data from Novartis presented at European Respiratory Society (ERS) Annual Congress

Novartis announced new analyses of data for once-daily Ultibro® Breezhaler® (investigational QVA149 - indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), which showed significant improvements in lung function, shortness of breath and health-related quality of life for chronic obstructive pulmonary disease (COPD) patients versus all comparators1,2. These data were part of 39 respiratory abstracts presented at the European Respiratory Society (ERS) Annual Congress in Barcelona, Spain.

9 Sep 2013

COPDF launches pocket consultant guide iPhone app for effective diagnosis, therapy of COPD

The COPD Foundation (COPDF) announces today the launch of its COPD Pocket Consultant Guide (PCG) iPhone app, a practical tool designed to facilitate easier, more effective diagnosis and therapy for Chronic Obstructive Pulmonary Disease (COPD) during daily clinical care.

7 Sep 2013